UNCLASSIFIED

Defense Technical Information Center
Compilation Part Notice

ADP013383

TITLE: Meso- and racemic-DMSA as Antidotes in Heavy Metal Poisoning

DISTRIBUTION: Approved for public release, distribution unlimited

This paper is part of the following report:

TITLE: Chemical and Biological Medical Treatment Symposium - Industry
II World Congress on Chemical and Biological Terrorism

To order the complete compilation report, use: ADA411272

The component part is provided here to allow users access to individually authored sections of proceedings, annals, symposia, etc. However, the component should be considered within the context of the overall compilation report and not as a stand-alone technical report.

The following component part numbers comprise the compilation report:

ADP013371 thru ADP013468

UNCLASSIFIED
13. Meso- AND racemic-DMSA AS ANTIDOTES IN HEAVY METAL POISONING

Maja Blanuša, Martina Piasek, Krista Kostial, Mark M. Jones and Pramod K. Singh

Institut for Medical Research and Occupational Health, Zagreb, Croatia; Department of Chemistry, Vanderbilt University, Nashville, TN, USA; Food Residue & Toxicology Laboratory, TN Department of Agriculture, Nashville, TN, USA

Lead, cadmium and mercury, well-known toxic metals, could be used in a chemical terrorist attack. Chelating agents are the only antidotes that promote toxic metals elimination from the body (1). At present meso-1,3-dimercaptosuccinic acid (meso-DMSA) is the optimal officially accepted antidote in lead or mercury poisoning that can be used orally (2). However, a racemic form of DMSA (rac-DMSA) seems to have higher stability constants with toxic metals than meso-DMSA but has not been yet thoroughly studied in vivo (3) and is not in human use. The results of our investigations presented in this paper have been obtained in experimental animal models in vivo to compare the efficacy of the mobilising potency of these two chelating agents in reducing toxic metal body retention (3-6).

The efficiency of these two DMSA isomers was tested after lead, mercury or cadmium poisoning in laboratory rats (female Wistar rats). Chelating therapy was started either immediately after or 3 to 5 days following metal application and lasted 2-4 days. Toxic metals were given either as a stable elements (Pb) or as radioactive isotopes (203Hg or 109Cd). At the end of the experiment stable lead was analysed by atomic absorption spectrometry (in tissues) and radioactive isotopes by measuring radioactivity in scintillation counters (separately in whole body and internal organs). Number of animals per group in each experiment was 8 to 11. The results were statistically evaluated by one-way ANOVA followed by post hoc Duncan’s multiple range test (at P<0.05).

Lead

First experiment was carried out on 8-week-old female rats by Pb loading (in the form of acetate) during five consecutive days with 5 mg Pb/kg body weight per day (3). Oral treatment with meso-DMSA (Aldrich Chemical Co., Milwaukee, WI, USA) or rac-DMSA (synthesis described in ref. 7) was administered for four days at the dose of 0.5 mmol/kg per day. At the end of the experiment lead concentrations were analysed in tissues of control (lead-exposed and untreated) and treated groups administered one of the two DMSA isoforms (Figure 1). Femur lead concentrations (reflecting whole body burden of lead) were significantly reduced. This effect was significantly greater after rac- than after meso-DMSA treatment. Lead concentrations in the kidneys were markedly reduced by treatment with both isoforms of DMSA and the effect was greater after rac-DMSA. Neither compound was efficient in reducing liver lead concentrations. Brain lead levels were reduced by both chelators with no difference between rac- and meso-DMSA treated groups.

Lead mobilization was further tested in 7-day-old suckling rats (4). Very young are at a higher risk than adults for health effects of lead. Five mg Pb/kg body weight was given as a single intraperitoneal injection. Meso- and rac-DMSA were administered twice at the dose of 0.5 mmol/kg body weight, 24 and 48 hours after Pb. At the end of the experiment lead was determined in carcass (skeleton without organs and fur), kidneys, liver and brain (Figure 2). The results showed again that rac-DMSA causes a greater effect in reducing tissue Pb concentrations (kidneys) than treatment with meso-DMSA.
**Mercury**

Mercury mobilisation was tested in 7-week-old rats by giving a single intraperitoneal injection of 0.5 mg/kg of HgCl₂ labelled with radioactive ⁴⁰³Hg (5). Chelators meso- or rac-DMSA were administered by gastric intubation during four days at the dose of 1 mmol/kg body weight per day. Results of whole body (Figure 3) and tissue retentions (Figure 4) showed that the lowest retention of ⁴⁰³Hg was obtained after rac-DMSA treatment in the whole body, liver and kidneys.

**Cadmium**

In an experiment on 4-week-old rats cadmium chloride was administered intraperitoneally with 0.03 mg CdCl₂ x H₂O labelled with radioactive ¹⁰⁹Cd (6). Intraperitoneal treatment with chelators started immediately and was repeated 24 hours later at the dose of 1 mmol/kg. After 6 days both DMSA isomer treatments caused a decrease of whole body ¹⁰⁹Cd retention with rac-DMSA being more efficient (Figure 5). The same reduction of ¹⁰⁹Cd was obtained in the liver, but in the kidneys only rac-DMSA was effective (Figure 6). This reduction of cadmium in the body was modest by both isoforms of DMSA being slightly more efficient with rac- than meso-DMSA.

In conclusion, results of our investigations show that the racemic isoform of DMSA is more efficient in reducing the body burden and target organ retention of toxic metals - lead, mercury and cadmium - than meso-DMSA. The efficiency of metal body burden reduction with rac-DMSA was ordered: mercury > lead > cadmium. These studies will be continued to assess whether rac-DMSA could be applied clinically.

**REFERENCES:**


**KEYWORDS**

Lead, cadmium, mercury, chelation therapy, 2,3-dimercaptosuccinic acid isoforms
Figure 1. Lead concentration in femur and organs of 8-week-old female rats after treatment with meso- or rac-DMSA (3). Animals were loaded intraperitoneally with 5 mg/kg body weight of lead (as acetate) for five consecutive days. Treatment with meso- or rac-DMSA was administered for four days at the dose of 0.5 mmol/kg each day. Significant difference to the control is indicated by one asterisk; two asterisks denote difference between treated groups.

Figure 2. Lead concentration in carcass and organs of suckling 7-day-old rats after treatment with meso- or rac-DMSA (4). Animals were loaded with a single intraperitoneal dose of 0.5 mmol/kg of lead (as acetate). Chelating agents meso- or rac-DMSA were given orally twice 24 and 48 h later at a dose of 0.5 mmol/kg. Significant difference to the control is indicated by one asterisk; two asterisks denote difference between treated groups.
Figure 3. Mercury-203 retention in the whole body of 7-week-old rats after treatment with meso- or rac-DMSA (5). Animals received 0.5 mg HgCl₂/kg body weight labelled with $^{203}$Hg by a single intraperitoneal injection. A four-day oral treatment with chelators started 5 days later at a dose of 1 mmol/kg. Significant differences between groups are indicated by different letters.

Figure 4. Mercury-203 retention in organs of 7-week-old rats after treatment with meso- or rac-DMSA (5). Animals received 0.5 mg HgCl₂/kg body weight labelled with $^{203}$Hg by a single intraperitoneal injection. A four-day oral treatment with chelators started 5 days later at a dose of 1 mmol/kg. Significant difference to the control is indicated by one asterisk; two asterisks denote difference between treated groups.
Figure 5. Cadmium-203 retention in the whole body of 4-week-old rats after treatment with meso- or rac-DMSA (6). Animals received 0.03 mg of CdCl\(_2\) x H\(_2\)O labelled with \(^{203}\)Cd in a single intraperitoneal injection. Two oral treatments with chelators started immediately and 24 hours later at a dose of 1 mmol/kg. Significant differences between groups are indicated by different letters.

Figure 6. Cadmium-203 retention in organs of 4-week-old rats after treatment with meso- or rac-DMSA (6). Animals received 0.03 mg of CdCl\(_2\) x H\(_2\)O labelled with \(^{203}\)Cd in a single intraperitoneal injection. Two oral treatments with chelators started immediately and 24 hours later at a dose of 1 mmol/kg. Significant difference to the control is indicated by asterisk.